|
UNITED STATES |
|||
|
SECURITIES AND EXCHANGE COMMISSION |
|||
|
Washington, D.C. 20549 |
|||
|
|
|||
|
SCHEDULE 14A |
|||
|
|
|||
|
Proxy Statement Pursuant to Section 14(a) of |
|||
|
|
|||
|
Filed by the Registrant ý |
|||
|
|
|||
|
Filed by a Party other than the Registrant o |
|||
|
|
|||
|
Check the appropriate box: |
|||
|
o |
Preliminary Proxy Statement |
||
|
o |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
||
|
o |
Definitive Proxy Statement |
||
|
o |
Definitive Additional Materials |
||
|
ý |
Soliciting Material Pursuant to §240.14a-12 |
||
|
|
|||
|
CHIRON CORPORATION |
|||
|
(Name of Registrant as Specified In Its Charter) |
|||
|
|
|||
|
|
|||
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
|||
|
|
|||
|
Payment of Filing Fee (Check the appropriate box): |
|||
|
ý |
No fee required. |
||
|
o |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
||
|
|
(1) |
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
|
(2) |
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
|
(3) |
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
|
|
|
|
|
|
|
|
(4) |
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
|
(5) |
Total fee paid: |
|
|
|
|
|
|
|
o |
Fee paid previously with preliminary materials. |
||
|
o |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
||
|
|
(1) |
Amount Previously Paid: |
|
|
|
|
|
|
|
|
(2) |
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
|
(3) |
Filing Party: |
|
|
|
|
|
|
|
|
(4) |
Date Filed: |
|
|
|
|
|
|
|
|
|
Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
|
RULE 14a-12 LEGEND
Participants in Solicitation
Chiron Corporation and Novartis AG and their respective directors & officers may be deemed to be participants in the solicitation of proxies from Chiron shareholders in connection with the merger. Information about the directors and executive officers of Chiron and their ownership of Chiron’s stock is set forth in the proxy statement for Chiron’s 2005 Annual Meeting of Shareholders. Investors can obtain more information when the Schedule 13e-3 and the proxy statement become available. Investors should read the Schedule 13e-3 and proxy statement carefully when they become available before making any voting decision.
|
|
|
November 22, 2005 |
Investor’s Business Daily leads the coverage today with an examination of the increasingly attractive market vaccines represents, as illustrated by the Novartis-Chiron deal. CNN provides a roundup of the current events surrounding avian flu. Rounding out the coverage is an interview with Biogen Idec’s VP of development, Burt Adelman, who discusses the company’s attempt to refocus its development capabilities.
Feature Story
Growth In Demand For Vaccines Is Key To Novartis-Chiron Deal
Investor’s Business Daily (Nov 22, 2005)
Until recently, drug makers avoided vaccines because profits were low and risks were high. That’s changing. Vaccines are becoming as lucrative as drugs. Drug maker Chiron’s vaccine business — as well as its access to other growth markets — are key reasons behind Novartis’ announcement that it will buy the 58% of Chiron it doesn’t already own. Read more>>
In Other News
Global Moves to Combat Flu Threat
CNN.com (Nov 22, 2005)
Global moves to combat the threat of avian flu are being stepped up, with China, the United States, Canada, Japan and North Korea all taking action to help stop the disease spreading. Read more >>
Biogen VP Evangelizes Over ‘Not Made Here’
Reuters (Nov 22, 2005)
But Adelman, Biogen Idec’s executive vice president of development, has sent out on something of a crusade to create a much more external-looking development strategy and business culture. “The first thing we need to do is establish a cultural alignment that the idea ‘not invented here’ is something to be proud of,” he said. Read more >>
|
Questions? |
|
New user? |
|
|
|
Corporate Communications |
|
Sign up for Chiron and the news |
|
Unsubscribe |